-
公开(公告)号：US20240207306A1
公开(公告)日：2024-06-27
申请号：US18594618
申请日：2024-03-04
发明人： Kazunori KATAOKA , Shigehito OSAWA , Satoshi UCHIDA , Kotaro HAYASHI , Anjaneyulu DIRISALA , Kazuko TOH
摘要： The present invention provides a composition that controls pharmacokinetics. Specifically, the present invention provides: a composition for controlling pharmacokinetics, the composition containing a polyvalent cation as an active ingredient; and a method for controlling pharmacokinetics using the polyvalent cation.
-
公开(公告)号：US11992555B2
公开(公告)日：2024-05-28
申请号：US17448263
申请日：2021-09-21
IPC分类号： A61K9/08 , A61K9/14 , A61K31/12 , A61K31/137 , A61K31/167 , A61K31/192 , A61K31/196 , A61K31/216 , A61K31/25 , A61K31/337 , A61K31/357 , A61K31/366 , A61K31/4178 , A61K31/4184 , A61K31/522 , A61K31/60 , A61K31/616 , A61K31/704 , A61K47/10 , A61K47/14 , A61K31/19 , A61K31/201
CPC分类号： A61K9/08 , A61K9/148 , A61K31/12 , A61K31/137 , A61K31/167 , A61K31/192 , A61K31/196 , A61K31/216 , A61K31/357 , A61K31/366 , A61K31/4178 , A61K31/4184 , A61K31/522 , A61K31/60 , A61K31/616 , A61K47/10 , A61K47/14 , A61K31/19 , A61K31/201 , A61K31/25 , A61K31/337 , A61K31/704
摘要： The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
-
公开(公告)号：US20240122943A1
公开(公告)日：2024-04-18
申请号：US18450253
申请日：2023-08-15
IPC分类号： A61K31/5575 , A61K8/69 , A61K9/00 , A61K9/06 , A61K31/165 , A61K31/191 , A61K31/216 , A61K31/25 , A61Q19/00 , A61Q19/06
CPC分类号： A61K31/5575 , A61K8/69 , A61K9/0014 , A61K9/0048 , A61K9/06 , A61K31/165 , A61K31/191 , A61K31/216 , A61K31/25 , A61Q19/005 , A61Q19/06
摘要： Provided are methods of reducing body fat in a subject, comprising locally (e.g., topically) administering one or more compounds of the Formula (I) and/or (V):
or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein X is —OR1, —SR2, or —NR3R4, and R1, R2, R3, R4, R5, R6, R7, R7′, Z, Y, n, y, and x, are as defined herein.-
4.发明公开公开(公告)号：US20230345938A1
公开(公告)日：2023-11-02
申请号：US18130042
申请日：2023-04-03
申请人： SMITH & NEPHEW, INC.
发明人： Aleksa JOVANOVIC , Lei SHI , Eric ROCHE , Paul RENICK
IPC分类号： A01N37/02 , A01N59/12 , A01N59/16 , A61L31/16 , A61K33/18 , A61K33/38 , A61L27/54 , A61L29/16 , A61L31/10 , A61L27/34 , A61L29/08 , A01N37/46 , A61L26/00 , A01N25/30 , A61L31/14 , A61L29/14 , A61L27/52 , A61K31/23 , A61K47/26 , A61K47/38 , A61K45/06 , A61K47/14 , A61K47/10 , A61K9/00 , A61K31/625 , A61P31/04 , A01N25/04 , A61K9/06 , A61K31/25 , A61K31/7036 , A61K31/79 , A61K38/12 , A61L27/02 , A61L27/04 , A61L27/30 , A61L29/02 , A61L29/10 , A61L31/02 , A61L31/08
CPC分类号： A01N37/02 , A01N59/12 , A01N59/16 , A61L31/16 , A61K33/18 , A61K33/38 , A61L27/54 , A61L29/16 , A61L31/10 , A61L27/34 , A61L29/085 , A01N37/46 , A61L26/0066 , A01N25/30 , A61L31/145 , A61L29/145 , A61L27/52 , A61K31/23 , A61K47/26 , A61K47/38 , A61K45/06 , A61K47/14 , A61K47/10 , A61K9/0014 , A61K31/625 , A61P31/04 , A01N25/04 , A61K9/06 , A61K31/25 , A61K31/7036 , A61K31/79 , A61K38/12 , A61L27/025 , A61L27/047 , A61L27/306 , A61L29/02 , A61L29/106 , A61L31/022 , A61L31/028 , A61L31/088 , A61L2300/404 , A61L2300/406 , A61L2420/04
摘要： The compositions of the present invention comprise at least one medium polarity oil and at least one antibacterial agent, the combination of which produces a synergistic antibacterial effect against bacterial biofilms. Methods are disclosed for the reduction of bacteria in and/or elimination of bacterial biofilms on biological and non-biological surfaces, as well as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms.
-
公开(公告)号：US11641856B2
公开(公告)日：2023-05-09
申请号：US17545409
申请日：2021-12-08
申请人： SMITH & NEPHEW, INC.
发明人： Aleksa Jovanovic , Lei Shi , Eric Roche , Paul Renick
IPC分类号： A01N59/12 , A61L29/16 , A01N37/02 , A01N59/16 , A61L31/16 , A61K33/18 , A61K33/38 , A61L27/54 , A61L31/10 , A61L27/34 , A61L29/08 , A01N37/46 , A61L26/00 , A01N25/30 , A61L31/14 , A61L29/14 , A61L27/52 , A61K31/23 , A61K47/26 , A61K47/38 , A61K45/06 , A61K47/14 , A61K47/10 , A61K9/00 , A61K31/625 , A61P31/04 , A01N25/04 , A61K9/06 , A61K31/25 , A61K31/7036 , A61K31/79 , A61K38/12 , A61L27/02 , A61L27/04 , A61L27/30 , A61L29/02 , A61L29/10 , A61L31/02 , A61L31/08
CPC分类号： A01N37/02 , A01N25/04 , A01N25/30 , A01N37/46 , A01N59/12 , A01N59/16 , A61K9/0014 , A61K9/06 , A61K31/23 , A61K31/25 , A61K31/625 , A61K31/7036 , A61K31/79 , A61K33/18 , A61K33/38 , A61K38/12 , A61K45/06 , A61K47/10 , A61K47/14 , A61K47/26 , A61K47/38 , A61L26/0066 , A61L27/025 , A61L27/047 , A61L27/306 , A61L27/34 , A61L27/52 , A61L27/54 , A61L29/02 , A61L29/085 , A61L29/106 , A61L29/145 , A61L29/16 , A61L31/022 , A61L31/028 , A61L31/088 , A61L31/10 , A61L31/145 , A61L31/16 , A61P31/04 , A61L2300/404 , A61L2300/406 , A61L2420/04 , A61K33/38 , A61K2300/00 , A61K33/18 , A61K2300/00 , A61K31/7036 , A61K2300/00 , A61K31/625 , A61K2300/00 , A61K31/23 , A61K2300/00
摘要： The compositions of the present invention comprise at least one medium polarity oil and at least one antibacterial agent, the combination of which produces a synergistic antibacterial effect against bacterial biofilms. Methods are disclosed for the reduction of bacteria in and/or elimination of bacterial biofilms on biological and non-biological surfaces, as well as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms.
-
公开(公告)号：US20230037322A1
公开(公告)日：2023-02-09
申请号：US17849949
申请日：2022-06-27
发明人： Rebecca Grange , John Allingham , Andrew Craig , P. Andrew Evans , Madhu Aeluri
IPC分类号： A61K31/45 , A61K31/221 , A61K31/25 , A61K31/341 , A61K31/397 , A61K31/4015 , A61K45/06 , A61K47/36 , C07C235/28 , C07C321/10 , C07D205/08 , C07D207/27 , C07D211/76 , C07D307/46
摘要： A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. Analogs of Mycalolide B have been prepared and tested in breast and ovarian cancer cell lines. The compounds show utility for inhibition of survival and proliferation of tumor cells. The compounds have been shown to disrupt actin.
-
公开(公告)号：US11471432B2
公开(公告)日：2022-10-18
申请号：US16915628
申请日：2020-06-29
发明人： Ralf Gold , Aiden Haghikia , Ulrich Matthes
IPC分类号： A61K31/19 , A61K31/215 , A61K31/25 , A61P17/06 , A61P37/02 , A61K31/714 , A61K9/20 , A61K9/48 , A61K31/225
摘要： The invention relates to a combination therapy for the prevention and/or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C3-C8 carboxylic acids, physiologically acceptable salts and/or esters thereof, and one or more fumaric acid esters and/or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.
-
8.发明申请公开(公告)号：US20220265596A1
公开(公告)日：2022-08-25
申请号：US17734523
申请日：2022-05-02
发明人： Steven LaBrenz , Patrick Stahl
摘要： The present invention is directed to pharmaceutical formulations of therapeutic proteins that comprise one or more polyethoxylated fatty alcohol (PFA) surfactants that are resistant to lipase mediated degradation. The present invention is also directed to methods of reducing aggregate and/or particulate formation in pharmaceutical formulations of therapeutic proteins and methods of maintaining a stable surfactant level in pharmaceutical formulations of therapeutic proteins.
-
公开(公告)号：US20220079183A1
公开(公告)日：2022-03-17
申请号：US17534299
申请日：2021-11-23
申请人： ENZYMOTEC LTD.
发明人： Asher WIDBERG , Gai BEN-DROR , Maria ILITZKY GUR , Yael HERZOG
IPC分类号： A23D9/04 , A23L33/115 , A23L33/00 , A23D9/007 , A61K8/37 , A61K8/67 , A61K8/92 , A61K31/25 , A61K31/355 , A61K35/20 , A61K36/31 , A61K36/888 , B01D3/10 , B01D3/12 , C11B3/12
摘要： Disclosed are processes for the preparation blends of at least one oil and at least one fat and the use of such blends as ingredients of various infant formulas and other articles manufacture.
-
公开(公告)号：US20220024961A1
公开(公告)日：2022-01-27
申请号：US17362028
申请日：2021-06-29
发明人： Pui-Kwong CHAN , May Sung Mak , Yun Wang
IPC分类号： C07H15/256 , A61K36/77 , A61K31/25 , A61K31/22 , C07C69/94 , A61K31/7048 , A61K31/704 , A61K31/56 , C07J63/00 , A61P33/04 , A61K31/235 , A61K31/343 , C07C69/78 , A61P35/04 , A61P33/02 , A61P33/06 , C07D307/77
摘要： This invention provides methods, processes, compounds and compositions for modulating the gene expression or secretion of adhesion proteins, angiopoietins or their receptors to cure diseases, for anti-angiogenesis and for treating parasites, wherein the adhesion proteins or receptors comprise fibronectin, integrins family, myosin, vitronectin, collagen, laminin, glycosylation cell surface proteins, polyglycans, cadherin, heparin, tenascin, CD 54, CAM, elastin and FAK; wherein the angiopoietins comprise angiopoietin 1, angiopoietin 2, angiopoietin 3, angiopoietin 4, angiopoietin 5, angiopoietin 6, angiopoietin 7, angiopoietin-like 1, angiopoietin-like 2, angiopoietin-like 3, angiopoietin-like 4, angiopoietin-like 5, angiopoietin-like 6, and angiopoietin-like 7; wherein the cancers comprise breast cancer, leukocyte cancer, liver cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer, cervical cancer, esophageal cancer, testicular cancer, spleenic cancer, kidney cancer, lymphatic cancer, pancreas cancer, stomach cancer and thyroid cancer.
-
-
-
-
-
-
-
-
-
搜索结果
283 条记录 (耗时 0.023 秒)
